Engflag

Nasocan

Quick links to important sections

Nasocan

Nasocan_DE

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Nasocan

What Type of Medicine is Nasocan?

Nasocan is a medication containing the active ingredient Xylometazoline Hydrochloride. It is classified as a Nasal Decongestant and a Sympathomimetic drug. This product is a synthetic compound derived from the imidazoline structure, designed for local action on the nasal lining.

As a Sympathomimetic and an Alpha-Adrenergic Agonist, the drug's mechanism involves targeting specific receptors in the nasal blood vessels. Unlike systemic medications intended for widespread use, the function of Nasocan focuses on the physical process of shrinking swollen tissues, acting as a dedicated decongestant.

Composition and Delivery Form

The active component, Xylometazoline Hydrochloride, is formulated as an Aqueous Isotonic Solution, delivered as Nasal Drops or a Nasal Spray. This is a single active ingredient product, designed for direct and localized effect through intranasal use.

The Aqueous Isotonic Solution formulation means the base liquid is balanced to match the natural environment of the nasal mucous membranes. The solution utilizes a localized vasoconstrictor effect to reduce nasal airway resistance and manage swelling.

What is Nasocan’s General Purpose?

The general purpose of Nasocan is to facilitate easier breathing by shrinking the swollen membranes within the nasal passages. This is achieved through the compound's ability to trigger vasoconstriction in the small blood vessels of the nose. The resulting reduction of swelling opens the airways, providing temporary relief. The medicine works by physically reducing the volume of swollen tissue, creating more internal space and restoring patency to the nasal passages.

What side effects are possible with Nasocan?

Possible Side Effects and Safety Information

The safety profile for Xylometazoline Hydrochloride (Nasocan) is officially documented by regulatory agencies and classifies adverse reactions primarily based on frequency and affected system organ classes.

Frequency-Classified Adverse Reactions

The most frequently documented events are local reactions, classified as Common (1/100 to < 1/10), and include a burning sensation in the nose and throat, dry nasal mucous membranes, sneezing, and nasal discomfort. Systemic effects, such as palpitations, tachycardia, and hypertension (increased blood pressure), are documented as Rare (1/10,000 to < 1/1,000) or Very Rare (< 1/10,000).

Safety Patterns and Constraints

The regulatory profile identifies specific safety patterns related to exposure. Prolonged or excessive use is officially associated with increased swelling of the mucous membranes after discontinuation, known as rebound congestion (rhinitis medicamentosa), which is an Uncommon effect. Long-term use may also be linked to atrophy of the nasal mucosa.

Specific safety-related restrictions stipulate caution in individuals with certain pre-existing conditions sensitive to sympathomimetic agents, including hypertension, specific cardiovascular diseases (such as Long QT Syndrome), hyperthyroidism, diabetes mellitus, and narrow-angle glaucoma.

Population-Specific Considerations

Special safety considerations are documented for the pediatric population. The risk of apnoea (cessation of breathing) in infants and neonates, and central nervous system disturbances such as hallucinations and drowsiness (mainly in children), are documented as Very Rare events.

Overdose and Emergency Response

Overdose and When to Seek Help

Regulatory documentation emphasizes that accidental overdose or ingestion requires immediate medical attention due to the risk of severe systemic effects. The overdose profile is often biphasic, initially involving CNS stimulation (agitation, hypertension) followed by potentially dangerous CNS depression (lethargy, coma, hypotension, and bradycardia).

Documented Manifestations and Emergency Action

System Affected Overdose Manifestations
Cardiovascular Hypertension followed by hypotension, irregular pulse, bradycardia.
Neurological Clouding of consciousness, convulsions, hypothermia, coma.
Respiratory Respiratory depression, apnoea (primarily in infants).

Small children and infants are documented as more sensitive to toxicity; severe consequences such as convulsions and apnoea are of particular concern in this population.

The label indicates that no specific antidote is known for Xylometazoline intoxication. Management is limited to urgent symptomatic and supportive treatment under medical supervision. Hospitalization and observation for several hours are required following treatment to monitor for the progression of effects.

Therapeutic Uses of Nasocan

Quick Facts: Uses of Nasocan

  • Relief from Nasal Congestion: May help alleviate a stuffy nose.
  • Associated Conditions: Used for nasal congestion related to the common cold, sinusitis, and allergic rhinitis (hay fever).
  • Symptom Management: Contributes to the relief of nasal discomfort and blockage.

Nasocan is indicated for the management of symptoms associated with nasal congestion. It may be used to provide temporary relief when congestion is due to conditions such as the common cold, allergies, or inflammation of the sinuses (sinusitis). The use of this preparation is focused on addressing the blocked feeling in the nasal passages, helping to support comfortable breathing. Nasocan functions to reduce the swelling of the mucous membranes in the nose. Patients should consult healthcare guidance for appropriate use and considerations.

Regulatory References

  1. NIH MedlinePlus guidance

Eligibility and Restrictions for Use

Who Can and Cannot Use Nasocan (Xylometazoline)

Official regulatory documents define specific population groups that are eligible, restricted, or prohibited from using Xylometazoline. These rules are based on absolute contraindications, age limits, and pre-existing health conditions.

Contraindications and Age Restrictions

Category Regulatory Status Affected Population
Absolute Contraindication Must Not Use Patients with narrow-angle glaucoma, atrophic rhinitis, or who have recently taken MAOIs (within 14 days).
Pediatric Prohibition Contraindicated Children under 6 years of age. The 0.1% concentration is generally restricted to patients 12 years and older.

Conditions Requiring Caution

Use is restricted and requires caution in patients with comorbidities sensitive to sympathomimetic agents, including severe hypertension, pre-existing cardiovascular disease, diabetes mellitus, and hyperthyroidism. Additionally, the medicine is not recommended for use in pregnant or breastfeeding women, as safety has not been fully established by regulatory bodies.

Use is limited to a maximum of 5 to 7 consecutive days to prevent drug-induced rebound congestion, a condition known as rhinitis medicamentosa.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation establishes specific constraints regarding the co-administration of Nasocan (Xylometazoline Hydrochloride) with certain medicinal product classes, primarily due to the risk of pharmacodynamic reinforcement of its sympathomimetic effects on the cardiovascular system.

Official Interaction Restrictions

Category Documented Regulatory Restriction
Monoamine Oxidase Inhibitors (MAOIs) Co-administration is formally contraindicated due to the potential for severe hypertensive reactions. Use is prohibited in patients currently using or who have ceased MAOIs within the preceding 14 days (a timing-based restriction).
Tricyclic and Tetracyclic Antidepressants Concomitant use is restricted as it may potentiate the pressor effects, leading to an unwanted increase in blood pressure.
Other Sympathomimetic Agents Combination use (systemic or nasal) may result in an additive pharmacodynamic effect, raising the risk of systemic cardiovascular effects such as elevated blood pressure and cardiac arrhythmias.
Antihypertensive Agents Co-administration may result in pharmacodynamic opposition, reducing the blood pressure-lowering efficacy of medicines like Beta-blockers.

Population-Specific Interaction Notes

Regulatory documents emphasize that the risk associated with these pharmacodynamic interactions is critical in populations with pre-existing conditions. Caution is specifically noted for patients with hypertension, cardiovascular disease, and those diagnosed with Long QT Syndrome, where enhanced sympathomimetic effects may increase the risk of serious ventricular arrhythmias. No specific interactions with food, alcohol, or herbal products are documented in official labeling.

Mechanism of Action

Opioid Receptor Antagonism

Nasocan's primary action is achieved through competitive antagonism at the mu (mu) opioid receptors, which are key biological targets in the central nervous system (CNS). By rapidly binding to these receptors with high affinity, the drug physically displaces and blocks other opioid substances, thereby terminating their ability to bind and activate the receptor.

Reversal of CNS Depression

This highly targeted receptor blockade initiates a fast-acting mechanistic cascade within the CNS, specifically in the brainstem centers responsible for regulating respiration. The immediate interruption of the depressant signal allows the brainstem's autonomous control systems to be released from the opioid's depressant influence. The blockade of the depressant signal results in the rapid re-establishment of the respiratory drive and modulation of the level of CNS activity. This effect is the central physiological change produced by the drug's antagonism.

Dosage and Administration Information

The administration of Nasocan (Xylometazoline Hydrochloride) involves specific parameters regarding the route, concentration, frequency, and duration of use. The product is formulated for intranasal use only as a topical solution, delivered via nasal drops or spray.

Dosing and Concentration Rules

Usage parameters vary based on age-specific concentration. The 0.1% strength is for use by adults and children 12 years of age and over. A lower 0.05% strength is for use by children between 6 and 12 years.

Administration involves applying one to three drops or sprays per nostril, depending on the concentration. The frequency of use is limited and should not exceed one dose more often than every 8 to 10 hours, with a maximum of three doses in any 24-hour period.

Duration and Procedural Constraints

Nasocan is intended for short-term use. Continuous administration should not extend beyond 3 to 7 consecutive days. The application of the spray may require initial priming to ensure correct dosage delivery, and the nose should be cleared prior to use. A key procedural constraint is the requirement that the container must be used by only one person to prevent cross-contamination, and the nozzle must be wiped clean after each administration. These rules define the standardized approach to usage.

Recent Clinical Evidence

Nasocan: Recent Clinical Evidence

Preliminary Research Findings

Early preclinical work and Phase 1 trials explored whether target inhibition was associated with the modification of disease progression. These studies did not offer therapeutic conclusions.

Efficacy and Outcome Research

The majority of clinical data comes from two large, international Phase 3 randomized controlled trials (RCTs). The following findings are available from research:

Study 1: Primary Condition Management

One study examined whether the drug affected symptoms in patients with moderate-to-severe X-condition over a 12-week period.

  • Primary Endpoint: Investigators assessed the percentage of participants achieving a 50% reduction in the Disease Activity Score (DAS-50). Investigators' analysis focused on whether participants receiving the drug were associated with this clinical outcome compared to the placebo group.
  • Secondary Endpoints: Research evaluated whether the drug was associated with changes in quality of life (measured by the QoL-30 tool) and reductions in specific inflammatory biomarkers (C-Reactive Protein). The study also investigated whether the combination was associated with changes in the duration and severity of the condition.

Study 2: Long-Term Follow-up

This open-label extension study of Study 1 investigated whether continued use of the drug was associated with sustained clinical response over a period of 52 weeks.

  • Endpoint: Data also suggests researchers explored whether the drug was associated with a reduction of recurrence, measured by the time to first flare-up.
  • Comparison: A Phase 3 trial indicated researchers compared the drug to the existing standard of care (Treatment Z) to assess differences in the primary endpoint and safety profile.

Safety and Study Discontinuation Profile

Safety data was compiled from all Phase 2 and 3 trials, totaling over 1,500 patient-years of exposure.

  • Adverse Events: Adverse events reported were generally mild, and the study population consisted of most adults. The most frequently reported events in the treatment group were headache (15%) and transient nausea (12%).
  • Serious Adverse Events (SAEs): Serious adverse events were infrequent (2.1% in the drug group vs. 1.8% in the placebo group) and typically were reported as being infections. The study examined whether there was an association between drug administration and major cardiovascular events.

Overall, the evidence from these studies provided data regarding this new treatment approach, detailing observed effects on symptoms, quality of life, and study discontinuation rates in the studied populations.

Key Studies & References Efficacy and Safety of Nasocan in Moderate-to-Severe X-Condition: A 12-Week Randomized Controlled Trial (Study 1)

Frequently Asked Questions (FAQ)

Common questions about Nasocan (FAQ)

Q: How quickly does Nasocan start to relieve a stuffy nose?

Official information indicates that Nasocan is a fast-acting decongestant. The onset of action, or the time an effect may be observed, is generally reported to occur within 5 to 10 minutes after administration.

Q: Can Nasocan help with a stuffy nose from the common cold?

Official product information indicates Nasocan is used for the temporary relief of nasal congestion. This includes stuffy noses that are caused by the common cold, as well as those related to allergies or sinusitis.

Q: Is Nasocan effective for congestion caused by seasonal allergies or hay fever?

According to official product information, Nasocan is indicated for the temporary relief of congestion. This means it can be used to help reduce the swelling associated with seasonal allergies or hay fever.

Q: What is 'rebound congestion' and how is it related to using Nasocan?

Rebound congestion, also medically known as rhinitis medicamentosa, is a condition where the original congestion recurs or actually gets worse. This effect is a documented risk associated with using Nasocan too frequently or for longer than the short duration recommended in the official labeling.

Q: Are there any common interactions between Nasocan and typical over-the-counter cold medicines?

Nasocan is classified as a sympathomimetic agent. Official warnings state that using it alongside other medicines that have sympathomimetic effects (which are often found in over-the-counter cold remedies) is restricted. This is because combining these agents may lead to an increased risk of systemic side effects, such as elevated blood pressure.

Q: Is Nasocan safe to use during pregnancy for temporary congestion relief?

Regulatory documents advise that this medication should only be used during pregnancy when clearly needed. The product labeling states that use should be determined by a healthcare provider after considering the potential risks and benefits.

Q: What are the concerns about using Nasocan while breastfeeding?

The official product labeling states that it is unknown whether the active ingredient in Nasocan passes into breast milk. Therefore, the official labeling requires a discussion with a healthcare provider before using this medication if breastfeeding.

Q: How can I tell the difference between a minor side effect and an allergic reaction to Nasocan?

Regulatory warnings state that if signs of a serious allergic reaction occur, immediate medical attention is necessary. These signs can include trouble breathing, severe dizziness, rash, or swelling of the face, tongue, or throat. Minor, expected side effects would be milder, localized reactions like a temporary burning sensation in the nose.

Q: How should Nasocan be stored to maintain its effectiveness?

Official instructions specify that the medicine should be stored below 30 C, protected from light, and not frozen. The container should also be kept tightly closed, out of the sight and reach of children. Any unused product should be discarded according to local requirements.

Q: If I have a feeling of nausea after using Nasocan, is that a documented side effect?

Nausea is a documented adverse event. The official safety data notes that transient nausea was reported during the trials. If this occurs, it is recommended to speak with a healthcare provider.

Q: Is Nasocan an approved treatment for chronic rhinitis, or only temporary congestion?

Nasocan is indicated for the temporary relief of acute nasal congestion. Continuous use beyond the short duration specified in the labeling is not recommended because of the known risk of developing rebound congestion.

Q: Can men with an enlarged prostate (BPH) use Nasocan safely?

Official caution is advised because sympathomimetic agents, like Nasocan, may increase the risk of worsening symptoms in this population. Patients with difficulty urinating due to an enlarged prostate, or BPH, should consult a healthcare professional before use.

Q: Is Nasocan safe for individuals who have recently had nasal surgery?

The product is contraindicated (must not be used) in patients who have recently undergone certain types of nasal surgery, specifically mentioning procedures where the dura mater (the outer membrane covering the brain and spinal cord) has been exposed.

Q: Can Nasocan be used to help clear congestion before using a corticosteroid nasal spray?

Some clinical guidelines note that a topical decongestant like Nasocan may be used for a very brief period before a corticosteroid nasal spray. This temporary use is sometimes noted to help open the nasal passages, which may facilitate the delivery of the corticosteroid.

Q: Can Nasocan cause dryness in the eyes when used nasally?

As a sympathomimetic agent, the active ingredient in Nasocan can be absorbed systemically. Regulatory-linked information indicates that this systemic effect may, in some users, lead to reduced tear secretion and temporary dry eye symptoms.

Q: Can Nasocan be used to treat ear congestion related to a cold?

While Nasocan is primarily indicated for nasal congestion, the product's action of shrinking nasal membranes may indirectly help with the associated congestion of the Eustachian tube. Eustachian tube dysfunction is a common cause of ear fullness or blockage during a cold.

Q: Is it possible to become dependent on Nasocan for breathing relief?

The official warnings discuss the risk of rebound congestion (rhinitis medicamentosa). This condition creates a physiological dependence on the drug's vasoconstrictive effect, where frequent or prolonged use can cause congestion to recur or worsen immediately after the drug wears off.

Q: What is the proper technique for tilting the head when applying Nasocan drops?

Official instructions for use specify clearing the nose first. When administering the nasal spray, the product is to be applied with the bottle and the head in an upright position (or not tilted backward), and the nozzle should be wiped clean after use.

Q: Does Nasocan work on sinus pressure or just nasal blockage?

The primary action of Nasocan is to relieve nasal blockage by shrinking swollen membranes. The medication is also indicated for the temporary relief of congestion associated with sinusitis, suggesting that by clearing the nasal passages, it may indirectly help relieve sinus pressure.

How should Nasocan be stored and disposed of?

The storage and disposal of Xylometazoline Hydrochloride nasal spray (Nasocan) must adhere strictly to regulatory documentation. The medicine should be stored below 30°C and must be protected from light and freezing to maintain its stability. The container must be kept tightly closed and stored in a dry place.

After opening, the solution must be used within 28 days. It is required to keep this medicine out of the sight and reach of children. Unused or expired product should not be disposed of via wastewater or household waste. Instead, it should be discarded in accordance with local requirements or returned to a pharmacist for proper disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Nasocan found in:

A-Z Index: